BR112012010868A2 - compostos inibidores da enzima lactato desidrogenase (ldh), pró-farmáco de composto, método de inibição da subunidade ldh-a da enzima ldh em mamíferos, método de inibição da enzima ldh-5 em mamíferos e uso de composto - Google Patents

compostos inibidores da enzima lactato desidrogenase (ldh), pró-farmáco de composto, método de inibição da subunidade ldh-a da enzima ldh em mamíferos, método de inibição da enzima ldh-5 em mamíferos e uso de composto

Info

Publication number
BR112012010868A2
BR112012010868A2 BR112012010868A BR112012010868A BR112012010868A2 BR 112012010868 A2 BR112012010868 A2 BR 112012010868A2 BR 112012010868 A BR112012010868 A BR 112012010868A BR 112012010868 A BR112012010868 A BR 112012010868A BR 112012010868 A2 BR112012010868 A2 BR 112012010868A2
Authority
BR
Brazil
Prior art keywords
ldh
enzyme
mammals
inhibition method
compound
Prior art date
Application number
BR112012010868A
Other languages
English (en)
Portuguese (pt)
Inventor
Lucacchini Antonio
Granchi Carlotta
Minutolo Filippo
Giannaccini Gino
Macchia Marco
Roy Sarabindu
Original Assignee
Universitá di Pisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitá di Pisa filed Critical Universitá di Pisa
Publication of BR112012010868A2 publication Critical patent/BR112012010868A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
BR112012010868A 2009-11-09 2010-11-05 compostos inibidores da enzima lactato desidrogenase (ldh), pró-farmáco de composto, método de inibição da subunidade ldh-a da enzima ldh em mamíferos, método de inibição da enzima ldh-5 em mamíferos e uso de composto BR112012010868A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000140A ITPI20090140A1 (it) 2009-11-09 2009-11-09 Composto inibitore dell'enzima lattato deidrogenasi (ldh) e composizione farmaceutica che comprende tale composto
PCT/EP2010/006740 WO2011054525A1 (en) 2009-11-09 2010-11-05 Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
BR112012010868A2 true BR112012010868A2 (pt) 2017-02-21

Family

ID=42244578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010868A BR112012010868A2 (pt) 2009-11-09 2010-11-05 compostos inibidores da enzima lactato desidrogenase (ldh), pró-farmáco de composto, método de inibição da subunidade ldh-a da enzima ldh em mamíferos, método de inibição da enzima ldh-5 em mamíferos e uso de composto

Country Status (11)

Country Link
US (1) US20120309794A1 (enExample)
EP (1) EP2499114A1 (enExample)
JP (1) JP2013510106A (enExample)
CN (1) CN102639497A (enExample)
AU (1) AU2010314367A1 (enExample)
BR (1) BR112012010868A2 (enExample)
CA (1) CA2780136A1 (enExample)
EA (1) EA201290316A1 (enExample)
IT (1) ITPI20090140A1 (enExample)
WO (1) WO2011054525A1 (enExample)
ZA (1) ZA201203993B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPI20110143A1 (it) 2011-12-20 2013-06-21 Univ Pisa Agenti terapeutici in grado di ridurre la produzione cellulare di acido lattico e composizioni farmaceutiche che comprendono tali composti
JP6194322B2 (ja) * 2013-01-25 2017-09-06 国立大学法人 岡山大学 乳酸脱水素酵素阻害剤およびそれを含有する医薬品
US9750761B2 (en) 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
FR3030516B1 (fr) * 2014-12-19 2019-12-27 Galderma Research & Development Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
CN107249583B (zh) 2015-02-09 2021-05-07 国立大学法人冈山大学 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂
US10954228B2 (en) 2016-06-29 2021-03-23 The Trustees Of The University Of Pennsylvania 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
EP4306108A1 (en) * 2022-07-11 2024-01-17 Theodossis Theodossiou 5-aminolevulinic acid, or an ester thereof for use in treatment of cancer based on the inhibition of lactate dehydrogenase
IT202400008665A1 (it) 2024-04-16 2025-10-16 Univ Pisa Agenti antivirali

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1923481A1 (de) * 1969-05-08 1970-11-12 Hoechst Ag Verfahren zur Herstellung von Amiden und Estern der 1-Hydroxy-benzimidazol-2-carbonsaeure
DE2060199A1 (de) * 1970-12-08 1972-07-06 Bayer Ag 1-Hydroxy-2-carbonamido-benzimidazol-3-oxide sowie deren Alkalisalze
GB2065098A (en) * 1979-12-07 1981-06-24 Erba Farmitalia N-substituted Thiazolyl Derivatives of 7-amino- cephalosporanic Acid
US4950602A (en) * 1987-02-20 1990-08-21 Cornell Research Foundation, Inc. Inhibition of lactate production by pyruvate adducts
US4762870A (en) * 1987-04-13 1988-08-09 The Firestone Tire & Rubber Company Rubber compositions modified with hydroxy-benz-imidazole oxides
JPH0331257A (ja) * 1989-06-28 1991-02-12 Kissei Pharmaceut Co Ltd インドール誘導体の製造方法
JPH0525140A (ja) * 1991-07-22 1993-02-02 Sankyo Co Ltd ベンズイミダゾール誘導体
US6169107B1 (en) * 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
EP0717984B1 (en) 1994-12-20 2004-11-03 Unilever Plc Lactate dehydrogenase inhibitors in cosmetic compositions
JP2935102B2 (ja) * 1996-07-04 1999-08-16 大塚化学株式会社 インドール−２−カルボン酸エステル誘導体及び該誘導体を有効成分とする農園芸用殺菌剤
WO1998036774A1 (en) 1996-12-18 1998-08-27 The Johns Hopkins University School Of Medicine Method of treating a lactate dehydrogenase-a (ldh-a)-associated disorder
EP1742637A4 (en) * 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
WO2006017494A2 (en) 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
JP2009020453A (ja) * 2007-07-13 2009-01-29 Fujifilm Corp 感光性組成物、硬化性組成物、カラーフィルタ用硬化性組成物、カラーフィルタ及びその製造方法、並びに、平版印刷版原版
WO2010014814A2 (en) 2008-07-30 2010-02-04 Wisconsin Alumni Research Foundation Glycosylated warfarin analogs and uses thereof

Also Published As

Publication number Publication date
ZA201203993B (en) 2014-11-26
ITPI20090140A1 (it) 2011-05-10
JP2013510106A (ja) 2013-03-21
AU2010314367A1 (en) 2012-05-31
WO2011054525A1 (en) 2011-05-12
CA2780136A1 (en) 2011-05-12
CN102639497A (zh) 2012-08-15
US20120309794A1 (en) 2012-12-06
EP2499114A1 (en) 2012-09-19
EA201290316A1 (ru) 2012-10-30

Similar Documents

Publication Publication Date Title
BR112012007828B8 (pt) compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase
AR085520A1 (es) Curativos epoxi hibridos de polieter
BRPI0715408B8 (pt) Processo para a preparação de 5-(1-alquiltio)alquilpiridinas 2-substituída
MX389666B (es) Induccion de celulas pluripotentes.
BR112016008593A8 (pt) composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína
BR112018012469A2 (pt) quinolina-3-carboxamidas como inibidores da h-pgds
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
CL2014000441A1 (es) Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.
BRPI0715176A8 (pt) compostos de heteroarila utéis como inibidores de enzimas de ativação e1
BR112012006406A2 (pt) "processo para a fabrição de n-acilbifenil alanina"
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
EA201290316A1 (ru) Соединения-ингибиторы фермента лактатдегидрогеназы (ldh) и фармацевтические композиции, содержащие эти соединения
CL2008000422A1 (es) El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.
BRPI0707493B8 (pt) composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto
BR112014005581A2 (pt) compostos inibidores de enzima
BR112015005416A2 (pt) produção de ácidos orgânicos por meio de fermentação em baixo ph
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
CO6382114A2 (es) Inhibidores de cinasa akt y p70 s6
BR112015005862A2 (pt) derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase
BRPI0921096A8 (pt) Composições e métodos para inibir a expressão dos genes de fator vii
BR112013021833A2 (pt) dispositivo fotodetector e de conversão com ganho (ec)
BR112015020716A2 (pt) processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto
BR112013019025A2 (pt) processo para o preparo de 4-amino-3-cloro-5-fluoro-6-(substituído) picolinatos
UA110807C2 (uk) КРИСТАЛІЧНІ ФОРМИ ГІДРОХЛОРИДУ (4A-R,9A-S)-1-(1H-БЕНЗОІМІДАЗОЛ-5-КАРБОНІЛ)-2,3,4,4А,9,9А-ГЕКСАГІДРО-1H-ІНДЕНО[2,1-b]ПІРИДИН-6-КАРБОНІТРИЛУ ТА ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ HSD 1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]